Nicox SA is an ophthalmic pharmaceutical company specializing in the development and commercialization of treatments for eye diseases. Founded in 1996 and headquartered in Sophia Antipolis, France, Nicox has built a portfolio of innovative therapies that address unmet needs in glaucoma, ocular inflammation and allergy. The company’s scientific approach leverages nitric oxide donation and selective enzyme inhibition to create differentiated mechanisms of action aimed at preserving vision and improving patient outcomes.
Nicox’s flagship product, latanoprostene bunod, is marketed in the United States under the brand name VYZULTA through an exclusive license and commercialization agreement with Bausch + Lomb. VYZULTA combines a prostaglandin analogue with nitric oxide donation to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition to VYZULTA, Nicox has advanced ZERVIATE (cetirizine ophthalmic solution), an antihistamine eye drop approved in the U.S. for the treatment of ocular itching associated with allergic conjunctivitis.
Beyond its marketed products, Nicox maintains a robust pipeline of clinical-stage assets. NCX 470, a novel nitric oxide-donating prostaglandin analogue for glaucoma, is advancing in Phase 3 trials in key markets, while NCX 4251, an anti-inflammatory prodrug for blepharitis, is exploring potential in Phase 2 studies. Nicox also collaborates with global partners to accelerate development and expand geographic reach, holding licensing arrangements in Europe, Asia-Pacific and emerging markets to ensure broad patient access.
Under the leadership of Chief Executive Officer Emmanuelle Roelandts and an experienced executive team, Nicox is committed to scientific innovation and strategic alliances. The company’s research activities are supported by state-of-the-art facilities in France and the United States, and its governance structure includes a board with expertise in pharmaceuticals, biotechnology and ophthalmology. Through its dual presence in Europe and North America, Nicox aims to continue delivering new ocular therapies that address evolving clinical needs worldwide.
AI Generated. May Contain Errors.
